Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain

• Hauptverfasser: Renata Zajączkowska (VerfasserIn), Katarzyna Pawlik (VerfasserIn), Katarzyna Ciapała (VerfasserIn), Anna Piotrowska (VerfasserIn), Agata Ciechanowska (VerfasserIn), Ewelina Rojewska (VerfasserIn), Magdalena Kocot-Kępska (VerfasserIn), Wioletta Makuch (VerfasserIn), Jerzy Wordliczek (VerfasserIn), Joanna Mika (VerfasserIn)
• Format: Buch
• Veröffentlicht: MDPI AG, 2023-07-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Neuropathic pain is a chronic condition that significantly reduces the quality of life of many patients as a result of ineffective pain relief therapy. For that reason, looking for new analgesics remains an important issue. Mirogabalin is a new gabapentinoid that is a specific ligand for the α2σ-1 a...